Research into the most prevalent tumors in developing countries significantly lags behind research into those cancers that ...

The investigation demonstrated that dual targeting of DOT1L and EZH2 effectively prevented human GCB-DLBCL xenograft growth ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system ...

announced groundbreaking clinical data from its noval in vivo CD19 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), a notoriously aggressive blood cancer. In a ...

New treatment advances are providing a lot of hope, and even a potential cure, for difficult to treat large B-cell lymphoma (LBCL). A new drug called liso-cel helps to modify a patient’s immune cells ...

“These results suggest that selecting the CD30 epitope and preserving less differentiated T cells ex vivo may enhance CAR-T therapy efficacy in patients with refractory Hodgkin lymphoma ...

The patient underwent surgical intervention, and postoperative pathological analysis confirmed the diagnosis of diffuse large B-cell lymphoma (DLBCL). Following surgery, the patient was initially ...

There are two main types: Hodgkin’s lymphoma: Hodgkin’s lymphoma involves large cancer cells called Reed-Sternberg (RS) cells. Non-Hodgkin’s lymphoma: RS cells are not present in non-Hodgkin ...

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

You've learned that you have diffuse large B-cell lymphoma (DLBCL). What happens now? A cancer diagnosis can feel overwhelming. You might not know what to do first. Start by having a conversation ...

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of non-Hodgkin lymphoma. Until recently, patients whose disease returned after standard chemo-immunotherapy faced limited ...